# Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis

> **NCT02945280** · PHASE4 · TERMINATED · sponsor: **Intermountain Health Care, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Deep Venous Thrombosis
- Upper Extremity Deep Venous Thrombosis
- Thrombus
- Venous Thromboembolism
- Deep Vein Thrombosis

## Interventions

- **DRUG:** apixaban

## Key facts

- **NCT ID:** NCT02945280
- **Lead sponsor:** Intermountain Health Care, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-22
- **Primary completion:** 2021-11-11
- **Final completion:** 2021-11-11
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** COVID-19 resource allocation
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02945280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02945280, "Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02945280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*